Cargando…
One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
PURPOSE: To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20 / 40 or better. METHODS: This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naï...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Ophthalmological Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904418/ https://www.ncbi.nlm.nih.gov/pubmed/33307629 http://dx.doi.org/10.3341/kjo.2020.0096 |
_version_ | 1783654924400197632 |
---|---|
author | Kwon, Ji Min Pak, Kang Yeun Lee, Jae Jung Sagong, Min Kim, Hyun Woong |
author_facet | Kwon, Ji Min Pak, Kang Yeun Lee, Jae Jung Sagong, Min Kim, Hyun Woong |
author_sort | Kwon, Ji Min |
collection | PubMed |
description | PURPOSE: To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20 / 40 or better. METHODS: This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naïve PCV were retrospectively reviewed. Patients with an initial BCVA of 20 / 40 or better and who had undergone intravitreal aflibercept injection were included. Patients were treated with three consecutive monthly injections, followed by pro re nata regimen according to the clinician’s discretion at variable interval visits. The proportions of eyes for which BCVA was maintained (≤ 0.2 logarithm of the minimum angle of resolution change) or improved at 12 months were evaluated. The changes of BCVA, central subfield macular thickness (CSMT), pigment epithelial detachment, and subretinal fluid also were assessed. RESULTS: A total of 86 eyes were included. The mean number of injections for 12 months of treatment was 5.4 ± 1.7. BCVA was maintained or improved in 94.2% (81 / 86) of cases. Mean BCVA (logarithm of the minimum angle of resolution) had changed from the baseline (0.23 ± 0.09) at 3 months (0.21 ± 0.14), 6 months (0.24 ± 0.22), and 12 months (0.20 ± 0.18), but with no statistical significance. CSMT had improved significantly from the baseline (336.1 ± 97.3 μm) at 3 months (223.6 ± 47.22 μm), 6 months (239.6 ± 64.2 μm), and 12 months (223.8 ± 47.9 μm). Pigment epithelial detachment was observed in 93% of cases at the baseline, 72.1% at 3 months, and 69.8% at 12 months, showing a significant decrease at all observation points. Subretinal fluid was observed in 91.9% of cases at the baseline, 20.9% at 3 months, and 29.1% at 12 months, showing a significant decrease at all observation points. CONCLUSIONS: In cases of PCV with good visual acuity, intravitreal aflibercept injections decreased CSMT and were effective in maintaining visual acuity. |
format | Online Article Text |
id | pubmed-7904418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean Ophthalmological Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-79044182021-03-03 One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity Kwon, Ji Min Pak, Kang Yeun Lee, Jae Jung Sagong, Min Kim, Hyun Woong Korean J Ophthalmol Original Article PURPOSE: To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20 / 40 or better. METHODS: This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naïve PCV were retrospectively reviewed. Patients with an initial BCVA of 20 / 40 or better and who had undergone intravitreal aflibercept injection were included. Patients were treated with three consecutive monthly injections, followed by pro re nata regimen according to the clinician’s discretion at variable interval visits. The proportions of eyes for which BCVA was maintained (≤ 0.2 logarithm of the minimum angle of resolution change) or improved at 12 months were evaluated. The changes of BCVA, central subfield macular thickness (CSMT), pigment epithelial detachment, and subretinal fluid also were assessed. RESULTS: A total of 86 eyes were included. The mean number of injections for 12 months of treatment was 5.4 ± 1.7. BCVA was maintained or improved in 94.2% (81 / 86) of cases. Mean BCVA (logarithm of the minimum angle of resolution) had changed from the baseline (0.23 ± 0.09) at 3 months (0.21 ± 0.14), 6 months (0.24 ± 0.22), and 12 months (0.20 ± 0.18), but with no statistical significance. CSMT had improved significantly from the baseline (336.1 ± 97.3 μm) at 3 months (223.6 ± 47.22 μm), 6 months (239.6 ± 64.2 μm), and 12 months (223.8 ± 47.9 μm). Pigment epithelial detachment was observed in 93% of cases at the baseline, 72.1% at 3 months, and 69.8% at 12 months, showing a significant decrease at all observation points. Subretinal fluid was observed in 91.9% of cases at the baseline, 20.9% at 3 months, and 29.1% at 12 months, showing a significant decrease at all observation points. CONCLUSIONS: In cases of PCV with good visual acuity, intravitreal aflibercept injections decreased CSMT and were effective in maintaining visual acuity. Korean Ophthalmological Society 2021-02 2021-02-05 /pmc/articles/PMC7904418/ /pubmed/33307629 http://dx.doi.org/10.3341/kjo.2020.0096 Text en © 2021 The Korean Ophthalmological Society https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kwon, Ji Min Pak, Kang Yeun Lee, Jae Jung Sagong, Min Kim, Hyun Woong One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity |
title | One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity |
title_full | One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity |
title_fullStr | One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity |
title_full_unstemmed | One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity |
title_short | One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity |
title_sort | one-year results of aflibercept treatment for polypoidal choroidal vasculopathy with good visual acuity |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904418/ https://www.ncbi.nlm.nih.gov/pubmed/33307629 http://dx.doi.org/10.3341/kjo.2020.0096 |
work_keys_str_mv | AT kwonjimin oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity AT pakkangyeun oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity AT leejaejung oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity AT sagongmin oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity AT kimhyunwoong oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity |